ERBB2 and neoplasm: T cells co-expressing HER2 and IL13-Rα2 CARs could effectively target and kill tumor cells that express either HER2 or IL13-Rα2, and showed particularly enhanced anti-tumor activity and antigen-dependent downstream signals compared with a single targeting strategy (45).